Whole-blood DNA methylation burden screening

Whole-blood DNA methylation burden screening is associated with clinical net benefit in silico (CHIP carriers versus unselected adults; assumed sensitivity 0.50) (At most 0.3 per 1,000 in unselected adults; up to 9.8 per 1,000 in CHIP carriers).

“net benefit was near zero in unselected adults (at most 0.3 per 1,000) and positive in CHIP carriers (up to 9.8 per 1,000).”

In silicoCHIP carriers versus unselected adults; assumed sensitivity 0.50

Blood DNA screen false positives rose with age

Research Square·Nov 12, 2026Preprint

Whole-blood DNA methylation burden screening predicts positive predictive value in silico (CHIP carriers versus unselected adults; assumed sensitivity 0.50) (1.8% in unselected adults; 9–29% in CHIP carriers; 54% with a repeat draw).

“positive predictive value was 1.8% in unselected adults and 9–29% in CHIP carriers (54% with a repeat draw)”

In silicoCHIP carriers versus unselected adults; assumed sensitivity 0.50whole blood

Blood DNA screen false positives rose with age

Research Square·Nov 12, 2026Preprint